SCHEMBL10112466

SCHEMBL10112466

Brc1cccc(N2CCN(C3CCCCC3)CC2)n1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 9/20 0.57
GAA P10253 1/20 0.49
ALOX15 P16050 1/20 0.49
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
DRD2 P14416 2/20 0.43
DRD3 P35462 2/20 0.43
ABCB1 P08183 1/20 0.43
HRH1 P35367 1/20 0.42
TSHR P16473 1/20 0.41
RAB9A P51151 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13363109 0.82 HRH3 (0.57) HRH3GAAALOX15ABCB1HRH1
SCHEMBL10112464 0.81 HRH3 (0.50) HRH3GAAALOX15ABCB1RAB9A
SCHEMBL957605 0.80 GRIN2D (0.56) GAAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL31598802 0.80 GRIN2D (0.56) GAAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL29615080 0.78 GRIN2D (0.57) GAAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL30569560 0.78 GRIN2D (0.57) GAAALOX15GRIN2DGRIN3BGRIN1
SCHEMBL15321816 0.78 GRIN2D (0.57) GAAALOX15GRIN2DGRIN3BGRIN1
SCHEMBL419024 0.78 GRIN2D (0.57) GAAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL22163222 0.77 HRH3 (0.55) HRH3GAAALOX15GRIN2DGRIN3B
SCHEMBL3972995 0.77 HRH3 (0.55) HRH3GAAALOX15GRIN2BDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541572-B2 Compounds for the treatment of inflammatory disorders MERCK SHARP & DOHME CORP. (US) 2013-09-24 US disclosed
US-8541572-B2 Compounds for the treatment of inflammatory disorders MERCK SHARP & DOHME CORP. (US) 2013-09-24 US disclosed
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed
WO-2010054279-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 HRH3 2441/4885GAA 57/4885ALOX15 520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.